Epigenomics AG (FRA:ECX) Notes Receivable: €0.00 Mil (As of Dec. 2025)


FRA:ECX Epigenomics AG FRA:ECX
13 GF Score
Price €0.95
GF Value €0.09
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Notes Receivable?

Epigenomics AG FRA:ECX +9.20% 13 Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 13/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Epigenomics AG's Notes Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Epigenomics AG Notes Receivable Historical Data

* Premium members only.

The historical data trend for Epigenomics AG's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epigenomics AG Notes Receivable Chart

Epigenomics AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Epigenomics AG Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:ECX
13GF Score
Epigenomics AG FRA:ECX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Epigenomics AG Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
Epigenomics AG (FRA:ECX) has a Notes Receivable of €0.00 Mil as of Dec. 2025. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Epigenomics AG and its competitors.
Is Epigenomics AG's Notes Receivable too high?
Epigenomics AG's current Notes Receivable is €0.00 Mil. Overall, Epigenomics AG has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's Notes Receivable compare to TMO and DHR?
Epigenomics AG's Notes Receivable of €0.00 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Medical Diagnostics & Research company?
A good Notes Receivable depends on the Medical Diagnostics & Research industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Epigenomics AG and its competitors. Epigenomics AG's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.95 — trading 955.6% above its estimated fair value. The current Notes Receivable is €0.00 Mil. Epigenomics AG's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current Notes Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Epigenomics AG (FRA:ECX) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.95 is trading 955.6% above its estimated GF Value™ of €0.09. GuruFocus considers Epigenomics AG to be Significantly Overvalued.

Key valuation signals for FRA:ECX:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €0.09 vs. price of €0.95 (955.6% above fair value)
  • GF Score™: 13/100 with 3 warning signs

No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
13GF Score

Get the complete analysis for FRA:ECX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.95
Price
€0.09
GF Value